Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 3/20 | 0.46 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | PKM | P14618 | 3/20 | 0.39 |
| ▸ | MMP8 | P22894 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | MGAM | O43451 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SI | P14410 | 1/20 | 0.37 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.37 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.37 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31033270 | 0.80 | MEN1 (0.41) | CYP4F2CYP4A11MEN1KMT2AALDH1A1 | |
| SCHEMBL993104 | 0.79 | ALDH1A1 (0.47) | ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL7065729 | 0.79 | MEN1 (0.44) | CYP4F2CYP4A11MEN1KMT2AALDH1A1 | |
| SCHEMBL535883 | 0.77 | MEN1 (0.52) | CYP4F2CYP4A11MEN1KMT2AALDH1A1 | |
| SCHEMBL16767838 | 0.77 | PKM (0.43) | CYP4F2CYP4A11MEN1KMT2AALDH1A1 | |
| SCHEMBL11304468 | 0.76 | MEN1 (0.41) | CYP4F2CYP4A11MEN1KMT2AALDH1A1 | |
| SCHEMBL1466385 | 0.75 | — | — | |
| SCHEMBL19906125 | 0.75 | PKM (0.39) | CYP4F2CYP4A11MEN1KMT2AALDH1A1 | |
| SCHEMBL9748657 | 0.74 | MMP8 (0.44) | CYP4F2CYP4A11MEN1KMT2AALDH1A1 | |
| SCHEMBL1313060 | 0.74 | CYP4F2 (0.47) | CYP4F2CYP4A11MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111032034-B | Spiro compounds and methods of making and using the same | H.隆德贝克有限公司 | 2023-05-02 | — | — | CN | disclosed |
| CN-110267963-B | MAGL inhibitors | H.隆德贝克有限公司 | 2022-04-01 | — | — | CN | disclosed |
| EP-3675848-B1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H LUNDBECK AS (DK) | 2022-03-23 | — | — | EP | disclosed |
| US-11161856-B2 | Spirocycle compounds and methods of making and using same | H. LUNDBECK A/S (DK) | 2021-11-02 | — | — | US | disclosed |
| US-20210214375-A1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2021-07-15 | — | — | US | disclosed |
| EP-3675848-A1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | Lundbeck La Jolla Research Center, Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| CN-111032034-A | Spiro compounds and methods of making and using the same | 隆德贝克拉荷亚研究中心有限公司 | 2020-04-17 | — | — | CN | disclosed |
| EP-3541821-A1 | MAGL INHIBITORS | Abide Therapeutics, Inc. (US) | 2019-09-25 | — | — | EP | disclosed |
| WO-2019046330-A1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABIDE THERAPEUTICS, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| US-10093635-B2 | MAGL inhibitors | ABIDE THERAPEUTICS, INC. (US) | 2018-10-09 | — | — | US | disclosed |
| WO-2018093947-A1 | MAGL INHIBITORS | ABIDE THERAPEUTICS, INC. (US) | 2018-05-24 | — | — | WO | disclosed |
| US-20180134674-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2018-05-17 | — | — | US | disclosed |
| US-20180134674-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134674-A1 | MAGL INHIBITORS | MAG, MAGI3, MGLL | CYP4F2 3841/4885CYP4A11 4418/4885MEN1 2056/4885 |
| US-11161856-B2 | Spirocycle compounds and methods of making and using same | OPRL1, MGLL, VKORC1L1 | CYP4F2 1444/4885CYP4A11 542/4885MEN1 1235/4885 |
| US-20210214375-A1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | OPRL1, MGLL, OPRK1 | CYP4F2 2356/4885CYP4A11 1089/4885MEN1 2363/4885 |
| US-10093635-B2 | MAGL inhibitors | MAG, MAGI3, MGLL | CYP4F2 3841/4885CYP4A11 4418/4885MEN1 2056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.